Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

New England Journal of Medicine study of Paxlovid shows no conclusive benefit in high risk patients.

"Conclusions
The time to sustained alleviation of all signs and symptoms of Covid-19 did not differ significantly between participants who received nirmatrelvir–ritonavir and those who received placebo. (Supported by Pfizer; EPIC-SR ClinicalTrials.gov number, NCT05011513.)"

"In this trial, we assessed the safety and efficacy of nirmatrelvir–ritonavir as an antiviral agent against SARS-CoV-2 in symptomatic, nonhospitalized, vaccinated or unvaccinated adults. Nirmatrelvir–ritonavir was not associated with a significantly shorter time to sustained alleviation of Covid-19 symptoms than placebo, and the usefulness of nirmatrelvir–ritonavir in patients who are not at high risk for severe Covid-19 has not been established."

Is it time for a Paxlovid vs Brilacidin clinical trial?

Farrell